Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSegro Regulatory News (SGRO)

Share Price Information for Segro (SGRO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 851.20
Bid: 0.00
Ask: 866.00
Change: 0.00 (0.00%)
Spread: 12.40 (1.453%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 851.20
SGRO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of a Prospectus

10 Mar 2017 11:47

RNS Number : 1637Z
SEGRO PLC
10 March 2017
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM THE UNITED STATES, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

SEGRO PLC

PUBLICATION OF RIGHTS ISSUE PROSPECTUS

10 March 2017

Further to the announcement by SEGRO plc (the "Company") earlier today relating to a fully underwritten rights issue to raise net proceeds of approximately £556 million (the "Rights Issue"), the UK Listing Authority has approved a prospectus dated 10 March 2017 (the "Prospectus").

Further details of the Rights Issue are set out in the Prospectus which is available on the Company's website (http://www.segro.com/investors) or can be inspected at the registered office of the Company at Cunard House, 15 Regent Street, London SW1Y 4LR during normal business hours on each Business Day up to and including 27 March 2017. Copies of the Prospectus will also be available from the Company's receiving agent, Equiniti Limited, at Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA.

A copy of the Prospectus will be submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM.

For further information, please contact:

SEGRO plc:

David Sleath, Chief Executive +44 (0) 20 7451 9120Soumen Das, Chief Financial Officer +44 (0) 20 7451 9110Harry Stokes, Head of Investor Relations and Research +44 (0) 20 7451 9124

 

BofA Merrill Lynch: +44 (0) 20 7628 1000

Joint Global Co-ordinator, Joint Sponsor and Joint Bookrunner

Simon Mackenzie SmithEdward PeelRichard AbelJames Fleming

 

UBS Investment Bank: +44 (0) 20 7567 8000

Joint Global Co-ordinator, Joint Sponsor and Joint Bookrunner

John WoollandFergus HorrobinThomas RaynsfordChristopher Smith

 

Media enquiries:

Richard Sunderland, FTI Consulting +44 (0) 20 3727 1000

Claire Turvey, FTI Consulting +44 (0) 20 3727 1000

 

 

Disclaimer

IMPORTANT NOTICE

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT. NOTHING IN THIS ANNOUNCEMENT SHALL CONSTITUTE AN OFFER OR INVITATION TO UNDERWRITE, BUY, SUBSCRIBE, SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SELL, ACQUIRE, DISPOSE OR SUBSCRIBE FOR THE NEW ORDINARY SHARES OR ANY OTHER SECURITIES. NOTHING IN THIS ANNOUNCEMENT SHOULD BE INTERPRETED AS A TERM OR CONDITION OF THE RIGHTS ISSUE. ANY DECISION TO PURCHASE, OTHERWISE ACQUIRE, SUBSCRIBE FOR, SELL OR OTHERWISE DISPOSE OF ANY SECURITIES MUST BE MADE ONLY ON THE BASIS OF THE INFORMATION CONTAINED IN AND INCORPORATED BY REFERENCE INTO THE PROSPECTUS. COPIES OF THE PROSPECTUS WILL BE AVAILABLE ON PUBLICATION FROM SEGRO'S REGISTERED OFFICE AND SEGRO'S WEBSITE: WWW.SEGRO.COM/INVESTORS.

The defined terms set out in the Prospectus apply in this Announcement.

The information contained in this Announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this Announcement or its accuracy or completeness. The information in this Announcement is subject to change.

Any offer to acquire the Company's securities pursuant to the offering referred to in these materials will be made, and any investor should make his/her investment decision, solely on the basis of information that is contained in the Prospectus. Copies of the Prospectus may be obtained at no cost from the Company, the Company's receiving agent, Equiniti Limited, or through the website of the Company at www.segro.com/investors, provided that the Prospectus will not, subject to certain exceptions, be available (whether through the website or otherwise) to Shareholders in the United States, South Africa and the other Excluded Territories. The Prospectus will give further details of the New Ordinary Shares, the Nil Paid Rights and the Fully Paid Rights (the "Securities") being offered pursuant to the Rights Issue.

The information contained herein is not for distribution or publication, whether directly or indirectly and whether in whole or in part, in or into the United States, South Africa or any of the other Excluded Territories. The distribution of this Announcement and/or the Prospectus and/or the Provisional Allotment Letter and/or the transfer of the Securities into jurisdictions other than the United Kingdom may be restricted by law, and, therefore, persons into whose possession this Announcement and/or the Prospectus and/or the Provisional Allotment Letter comes should inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws of such jurisdiction. In particular, subject to certain exceptions, the Prospectus and the Provisional Allotment Letter should not be distributed, forwarded to or transmitted in or into the United States, South Africa or any of the other Excluded Territories. There will be no public offer of Securities in the United States, South Africa or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction.

The Securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States.

The offering of the Securities is only being made in Canada pursuant to exemptions from the prospectus and registration requirements that otherwise apply to a distribution of securities under applicable Canadian securities legislation. Any offer or solicitation in Canada must be made through a dealer that is appropriately registered under the laws of the applicable province or territory of Canada, or pursuant to an exemption from that requirement. Any resale of the Securities in Canada must be made under available statutory exemptions.

Merrill Lynch International and UBS Limited are acting as Joint Global Coordinators, Joint Bookrunners and Joint Sponsors for the Company, and Barclays Bank PLC, BNP Paribas and HSBC Bank plc are acting as Co-Bookrunners for the Company (collectively the "Bookrunners"). Each of the Bookrunners is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for the Company and no one else in connection with the Rights Issue, and will not regard any other person (whether or not a recipient of this Announcement) as its client in relation to the Rights Issue and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in connection with the Rights Issue or any other matters referred to in this Announcement.

In connection with the Rights Issue, each of the Bookrunners, and any of their respective affiliates, acting as investor for its own account, may take up the Securities and/or related instruments in the Rights Issue and in that capacity may retain, purchase or sell for its own account such securities and any New Ordinary Shares or related investments and may offer or sell such New Ordinary Shares or other investments otherwise than in connection with the Rights Issue. Accordingly, references to New Ordinary Shares being offered or placed should be read as including any offering or placement of New Ordinary Shares to any of the Bookrunners or any of their respective affiliates acting in such capacity. None of the Bookrunners intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so. In addition, the Bookrunners or their affiliates may enter into financing arrangements (including swaps) with investors in connection with which the Bookrunners (or their affiliates) may from time to time acquire, hold or dispose of New Ordinary Shares.

This Announcement is being issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability whatsoever is or will be accepted by the Bookrunners nor any of their respective affiliates or agents (or any of their respective directors, officers, employees or advisers) for the contents of the information contained in this Announcement, including its accuracy, completeness, fairness or verification or regarding the legality of any investment in the Securities or any other written or oral information made available to or publicly available to any interested party or its advisers, or any other statement made or purported to be made by or on behalf of any Bookrunner or any of their respective affiliates in connection with the Company, the New Ordinary Shares or the Rights Issue and nothing in this Announcement is or shall be relied upon as, a promise or representation in this respect, whether as to the past or the future and any responsibility therefor is expressly disclaimed. The Bookrunners and each of their respective affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise in respect of this Announcement or any such statement and no representation or warranty, express or implied, is made by any Bookrunner or any of their respective affiliates as to the accuracy, completeness or sufficiency of the information contained in this Announcement.

This Announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Securities. Any investment decision to buy Securities in the Rights Issue must be made solely on the basis of publicly available information, which has not been independently verified by the Bookrunners. The contents of this Announcement are not to be construed as legal, business, financial or tax advice. None of the Company, the Bookrunners, or any of their respective representatives, is making any representation to any offeree or purchaser of the Securities regarding the legality of an investment in the Securities by such offeree or purchaser under the laws applicable to such offeree or purchaser. Each prospective investor should consult his, her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice in connection with the purchase of the Securities. In making an investment decision, each investor must rely on their own examination, analysis and enquiry of the Company and the terms of the Rights Issue, including the merits and risks involved.

The New Ordinary Shares to be issued pursuant to the Rights Issue will not be admitted to trading on any stock exchange other than the London Stock Exchange.

The most recent Annual and Interim Reports and other information are available on the SEGRO website at www.segro.com/investors. Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.

This Announcement does not constitute a recommendation concerning the Rights Issue.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PDIBBGDXUSBBGRG
Date   Source Headline
2nd Sep 20167:00 amRNSPLACING TO FUND DEVELOPMENT PROGRAMME
1st Sep 20162:00 pmRNSBlock listing Interim Review
31st Aug 20162:30 pmRNSTotal Voting Rights
26th Aug 20167:00 amRNSDisposal
25th Aug 20162:30 pmRNSScrip Dividend Scheme - Scrip Calculation Price
24th Aug 20162:30 pmRNSHolding(s) in Company
18th Aug 20162:30 pmRNSHolding(s) in Company
29th Jul 201612:36 pmRNSTotal Voting Rights
26th Jul 20167:01 amRNSSEGRO appoints Soumen Das as CFO
26th Jul 20167:00 amRNSRESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2016
30th Jun 20163:00 pmRNSTotal Voting Rights
15th Jun 20167:00 amRNSSEGRO TRANSFER INTO SELP JOINT VENTURE
8th Jun 20163:00 pmRNSDirector/PDMR Shareholding
31st May 20163:30 pmRNSTotal Voting Rights
27th May 201612:00 pmRNSDirector/PDMR Shareholding
20th May 20161:00 pmRNSAdditional Listing
16th May 201611:30 amRNSDirector/PDMR Shareholding
11th May 20167:00 amRNSSEGRO arranges bank facilities totalling EUR780m
9th May 20163:00 pmRNSDirector/PDMR Shareholding
9th May 201611:30 amRNSAdditional Listing
5th May 20167:00 amRNSInvestor and analyst event
3rd May 201611:30 amRNSScrip Dividend Alternative - Additional Listing
29th Apr 20163:30 pmRNSBlock listing Interim Review
22nd Apr 20162:33 pmRNSResult of AGM
21st Apr 20167:00 amRNSTrading Statement
13th Apr 20167:00 amRNSDirectorate Change
12th Apr 20163:30 pmRNSDirector/PDMR Shareholding
4th Apr 20162:30 pmRNSScrip Dividend Scheme - Scrip Calculation Price
7th Mar 20161:40 pmRNSAnnual Financial Report
1st Mar 20163:00 pmRNSDirector Declaration
25th Feb 20163:00 pmRNSDirector/PDMR Shareholding
24th Feb 20163:00 pmRNSHome Member State Disclosure
19th Feb 20167:00 amRNSResults for the year ended 31 December 2015
18th Feb 20167:00 amRNSSEGRO ENTERS EXCLUSIVE PARTNERSHIP WITH ROXHILL
12th Feb 20167:22 amRNSSTATEMENT REGARDING PRESS COMMENT
29th Jan 20162:38 pmRNSSEGRO COMPLETES SALE OF SLOUGH OFFICE PORTFOLIO
27th Jan 20163:00 pmRNSHolding(s) in Company
15th Jan 20167:00 amRNSAPPOINTMENT OF CHAIRMAN-DESIGNATE
24th Dec 20157:00 amRNSSALE OF SLOUGH OFFICE PORTFOLIO FOR £325 MILLION
15th Dec 20157:00 amRNSSEGRO AND HERMES COMPLETE INDUSTRIAL ASSET SWAP
4th Dec 201510:44 amRNSDirector/PDMR Shareholding
3rd Dec 20153:19 pmRNSChange of Auditor
30th Nov 20154:00 pmRNSTotal Voting Rights
23rd Nov 20157:00 amRNSSEGRO ACQUIRES EUR93M NETHERLANDS PORTFOLIO
30th Oct 20152:30 pmRNSTotal Voting Rights
22nd Oct 20157:00 amRNSTrading Update
6th Oct 20153:45 pmRNSDirector/PDMR Shareholding
30th Sep 20152:30 pmRNSTotal Voting Rights
30th Sep 201511:55 amRNSScrip Dividend Alternative - Additional Listing
21st Sep 20157:00 amRNSAcquisition of Ventura Park in swap transaction

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.